Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CytoDyn Inc.
Report date January 10, 2019 · Filed January 10, 2019
Section 16 reporting ended · disclosed 2019-01-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2019-05-29 | Direct | 0 |
Reported balance
After 2019-01-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-10 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2024-05-29 | Direct | 100,000 |
Reported balance
After 2019-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-10 · Grant · Acquired 100,000 · Balance 100,000 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2019-06-01 | Direct | 0 |
Reported balance
After 2019-01-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-10 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2024-06-01 | Direct | 50,000 |
Reported balance
After 2019-01-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-10 · Grant · Acquired 50,000 · Balance 50,000 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions.
F2: Such options were fully vested and exercisable as of the date of the reported transactions.
GILEAD SCIENCES, INC.
Report date May 08, 2007 · Filed May 15, 2007
Section 16 reporting ended · disclosed 2007-05-15. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 14,630 | $0.00 Strike: $8.54 | $0.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · derivative · entry 32 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,630 shares Expires 2009-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest over a period of five years beginning on date of grant. Twenty percent (20%) vests on the first anniversary date of the grant, and the remaining balance vests five percent(5%)every three months thereafter. Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,370 | $0.00 Strike: $8.54 | $0.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · derivative · entry 31 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,370 shares Expires 2009-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest over a period of five years beginning on date of grant. Twenty percent (20%) vests on the first anniversary date of the grant, and the remaining balance vests five percent(5%)every three months thereafter. Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 498 | $38.81 | $19,327.38 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 30 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,518 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 802 | $38.81 | $31,125.62 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 29 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,016 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,200 | $38.80 | $46,560.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 28 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,818 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $38.79 | $96,975.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 27 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,018 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,100 | $38.78 | $158,998.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 26 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,518 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,300 | $38.77 | $89,171.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 25 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,618 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,610 | $38.76 | $294,963.60 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 24 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,918 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,090 | $38.76 | $42,248.40 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 23 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,528 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 13,540 | $38.75 | $524,675.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 22 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,618 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,960 | $38.75 | $308,450.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 21 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,158 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,100 | $38.74 | $42,614.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 20 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,118 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,644 | $38.73 | $141,132.12 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 19 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,218 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,056 | $38.73 | $40,898.88 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 18 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,862 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,900 | $38.72 | $73,568.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 17 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,918 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,700 | $38.71 | $143,227.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 16 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,818 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $38.70 | $11,610.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 15 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,518 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $38.69 | $38,690.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 14 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,818 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,400 | $38.68 | $92,832.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 13 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,818 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $38.66 | $11,598.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 12 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,218 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,300 | $38.65 | $50,245.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 11 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,518 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 600 | $38.64 | $23,184.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 10 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,818 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,200 | $38.63 | $46,356.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 9 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,418 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,100 | $38.62 | $81,102.00 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 8 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,618 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,430 | $38.61 | $55,212.30 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 7 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,718 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 9,370 | $38.61 | $361,775.70 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 6 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,148 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommn Stock | 18,512 | $7.40 | $136,961.03 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 5 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,016 | $7.08 | $42,582.45 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 4 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 29,990 | $7.08 | $212,275.22 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 3 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 14,630 | $8.54 | $124,927.03 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 2 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 9,370 | $8.54 | $80,011.37 |
DisclosureSEC source: 0001179110-05-009718 · edgar.xml · nonDerivative · entry 1 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: This report on Form 4 is the first of two to report insider transactions that were executed on May 10, 2005. Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,800 | $38.88 | $69,984.00 |
DisclosureSEC source: 0001179110-05-009719 · edgar.xml · nonDerivative · entry 8 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 518 | $38.87 | $20,134.71 |
DisclosureSEC source: 0001179110-05-009719 · edgar.xml · nonDerivative · entry 7 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $38.87 | $38,870.00 |
DisclosureSEC source: 0001179110-05-009719 · edgar.xml · nonDerivative · entry 6 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,318 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $38.86 | $19,430.00 |
DisclosureSEC source: 0001179110-05-009719 · edgar.xml · nonDerivative · entry 5 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,318 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $38.85 | $7,770.00 |
DisclosureSEC source: 0001179110-05-009719 · edgar.xml · nonDerivative · entry 4 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,818 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $38.84 | $3,884.00 |
DisclosureSEC source: 0001179110-05-009719 · edgar.xml · nonDerivative · entry 3 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,018 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $38.83 | $19,415.00 |
DisclosureSEC source: 0001179110-05-009719 · edgar.xml · nonDerivative · entry 2 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,118 Read SEC document |
| May 10, 2005 Filed May 12, 2005 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 900 | $38.82 | $34,938.00 |
DisclosureSEC source: 0001179110-05-009719 · edgar.xml · nonDerivative · entry 1 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,618 F1 · balance_after: This report on Form 4 is the second of two to report insider transactions that were executed on May 10, 2005. Read SEC document |
| January 26, 2005 Filed Jan 28, 2005 21:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 81,877 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001179110-05-001855 · edgar.xml · derivative · entry 2 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,877 Underlying: Common Stock · 81,877 shares Expires 2015-01-26 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 26, 2006, the first anniversary date of the grant. The balance will vest every three months thereafter until fully vested on January 26, 2015. Read SEC document |
| January 26, 2005 Filed Jan 28, 2005 21:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantIncentive Stock Option (right to buy) · Derivative | 3,123 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001179110-05-001855 · edgar.xml · derivative · entry 1 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,123 Underlying: Common Stock · 3,123 shares Expires 2015-01-26 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 26, 2006, the first anniversary date of the grant. The balance will vest every three months thereafter until fully vested on January 26, 2015. Read SEC document |
| July 28, 2004 Filed Jul 29, 2004 19:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $58.23 | $0.00 |
DisclosureSEC source: 0001179110-04-015473 · edgar.xml · derivative · entry 1 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2014-07-28 F1 · derivative.exercise_date: Option vests 20% on the first anniversary date of the grant, the remaining balance will vest quarterly over a four year period beginning 7/28/2005. The option will be fully vested on 07/28/2009. Read SEC document |
| January 28, 2004 Filed Jan 30, 2004 22:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 58,363 | $0.00 Strike: $61.06 | $0.00 |
DisclosureSEC source: 0001179110-04-002086 · edgar.xml · derivative · entry 2 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,363 Underlying: Common Stock · 58,363 shares Expires 2014-01-28 F1 · derivative.exercise_date: Options (split between incentive and non qualified stock options) vest 20% on the first anniversary date of the grant, and the remaining balance will vest quarterly over a four year period beginning on 1/28/05. The option will be fully vested by 1/28/09. X Read SEC document |
| January 28, 2004 Filed Jan 30, 2004 22:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantIncentive Stock Option (right to buy) · Derivative | 1,637 | $0.00 Strike: $61.06 | $0.00 |
DisclosureSEC source: 0001179110-04-002086 · edgar.xml · derivative · entry 1 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,637 Underlying: Common Stock · 1,637 shares Expires 2014-01-28 F1 · derivative.exercise_date: Options (split between incentive and non qualified stock options) vest 20% on the first anniversary date of the grant, and the remaining balance will vest quarterly over a four year period beginning on 1/28/05. The option will be fully vested by 1/28/09. X Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $34.33 | $0.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · derivative · entry 24 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,278 Underlying: Common Stock · 10,500 shares Expires 2011-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $32.88 | $0.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · derivative · entry 23 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 9,000 shares Expires 2012-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $31.12 | $0.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · derivative · entry 22 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 5,000 shares Expires 2012-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $14.80 | $0.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · derivative · entry 21 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,512 Underlying: Common Stock · 16,000 shares Expires 2011-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,997 | $0.00 Strike: $14.16 | $0.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · derivative · entry 20 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,995 Underlying: Common Stock · 10,997 shares Expires 2010-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.